• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Syngene

    Adare Pharma Solutions

    Reed-Lane

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services

    Reed-Lane

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Sterile Manufacturing: Future Trends and Challenges

    By the middle of this century, biopharmaceuticals are set to overtake all other pharma sales

    Sterile Manufacturing: Future Trends and Challenges
    Related CONTENT
    • Vetter continues its successful performance at the 2021 CMO Leadership Awards
    • Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    • Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    • Life Science Success Podcast: Matt Hicks
    • Trial Runners
    Igor Gorsky, Concordia Valsource10.11.17
    In the last 10 years we are experiencing an unprecedented growth of biopharmaceutical therapies. They have shown to provide much more effective treatments to patients than traditional medicine, which has until now been dominant for several centuries. With advancements in mapping and understanding human genome, this trend will only increase and increase very rapidly. Analysis of the biotech market shows that if extrapolated to the year 2030 it will reach approximately 45%1 of all global pharma sales and by the middle of the century will definitely overtake all other pharmaceutical sales and become a therapy of choice for new generations.

    Along with the growth of the biotechnology market, we are also observing the advancement of new technologies, new testing techniques, as well as implementation of risk-based lifecycle approaches based on knowledge management. Almost every company at this point in time is well aware and actively implementing some type of risk management strategy. Although future trends appear optimistic in general, unfortunately, some segments of the pharmaceutical industry remain conservative and adverse to change. Maintaining an attitude of, “If it’s not broken, don’t fix it,” changes and progress present considerable challenges for these segments of the industry.

    This is especially visible in contract research organizations (CRO) and contract manufacturing organizations (CMOs). There are a great number of factors influencing development at CROs and CMOs. Among many of these factors are:
    • Rapid growth of biological research by academia and start-up clinical research firms, which don’t have capabilities for commercial-scale production;
    • Steady increase in grants and investments for biotechnology research and commercialization, which stands currently at approximately $300 billion and will rapidly more than double by 2030;
    • General rise in therapeutic treatments for the world population, as the Baby Boomer generation ages and life expectancy increases; and
    • Additional capacity for established pharmaceutical firms, especially for the products that may require aseptic production or special containment, such as many oncological products.
    It is very important for contract manufacturers to stay current and update their facilities so that new generations of products can be manufactured with fewer risks and interventions that may cause contamination, to train their personnel in the latest advancements in technology and finally to obtain, qualify and utilize this new technology.
    These times will be challenging and are approaching rapidly. It is discouraging to note that while reviewing recently issued FDA Forms 483 and Warning Letters we are still finding many firms are not up to par and compliant with elementary aseptic practices.

    FDA observations
    A recent Warning letter for one manufacturer states that, “During our inspection, we reviewed reports from multiple investigations that you conducted into complaints regarding the presence of visible particulates in several of your sterile injectable products. The presence of visible particulates in sterile injectable products is an indication of a significant loss of control in your manufacturing process and represents a severe risk of harm to patients. We documented that your investigations into these product quality defects were inadequate and failed to spur appropriate corrective actions and preventive actions.”

    In another Warning Letter, the FDA depicts 1,500 complaints from 2012 to 2016 related to leaking, under-filled or empty bottles of a sterile solution. In its root causes investigation, the company has indicated issues with the bottle within the filling process—e.g. when the bottle isn’t correctly placed in the filling machine. Several manual interventions in the aseptic process were necessary, whereby defects haven’t always been detected, particularly when cracks occur in the glass bottle under the cap. Moreover, such cracks may develop a few days after the filling process, as noticed in the investigation.2

    Yet another contract manufacturer failed to adhere to basic aseptic manufacturing practices and did not design and qualify its facility to aseptic process requirements. That Warning letter cites, “Failure to develop, conduct, control, and monitor production processes to ensure that [a product] conforms to its specifications, as required by code of federal regulation. For example: your procedure, ‘Aseptic Process Simulation Program’ is not adequately established. Specifically, there is no definition of what an intervention is for performing activities that are not considered routine and need to be assessed when performing an aseptic process simulation (APS). Interventions that were performed and approved during APSs are not written in a procedure; therefore operators do not know what interventions they can perform during routine production unless they review previous APSs.”

    In addition, during this inspection regulators added that while products were filled in an aseptic fill room and area, “qualification of this room and area per ISO 14644-1, was not adequately performed. Key process parameters such as HEPA filter air velocities were not adequately established. The qualifications did not determine a specification for air velocities for the HEPA filters to adequately control the process. There was no evidence that unidirectional airflow was obtained through a smoke study. Total particulate air monitoring was only performed at a rest state. There was no monitoring at an operational state. There was no viable particulate monitoring.”

    In a recent FDA Office of Compliance presentation,3 three regulators highlighted some key problem areas and trends in Warning Letters observations that included:
    • Data integrity
    - Lack of control over access to computerized systems
    - Non-contemporaneous record keeping
    - Deletion, falsification, alteration, or other manipulation of data
    • Supply chain
    - API re-packers/re-labelers issues
    - Contract manufacturers issues
    - Heparin supply chain challenges
    • Sterility assurance
    - Compounding and conventional lack of sterility
    - Aseptic technique failures, environmental monitoring failures, design and qualification of facilities
    • Rudimentary CGMP
    - Release testing
    - Cleaning, equipment maintenance, basic sanitation failures
    - Cross-contamination risks
    - More often for non-application/OTC monograph drugs
    • Delay/Deny/Limit/Refuse

    As shown in the above list contract manufacturing and sterility assurance are among the issues cited by FDA, which is why it is more important than ever to re-emphasize to contract manufacturers the basic CGMP principles proclaimed almost 15 years ago in, described at the time as, “a significant initiative, pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century, to enhance and modernize the regulation of pharmaceutical manufacturing and product quality—to bring a 21st century focus to this critical FDA responsibility.”

    This initiative was significant for many reasons, in which risk and knowledge management, process understanding, validation, monitoring and optimization would be playing a much more prominent role than formal data gathering. It would hopefully help manufacturers to establish sustainable cultures based on an understanding of risks to manufacturing processes as well as building of knowledge bases about their products and processes. 

    However, unfortunate examples such as those highlighted earlier still exist and tend to involve a considerable number of contract manufacturers. At the same time though, we also see a trend where some CMO firms are forward thinking and investing in modern designs and future technologies.

    Recently there have been several mergers and acquisitions with the apparent goal of expanding contract manufacturing capacity and capabilities. This includes sterile pharmaceutical and biopharmaceutical expansion globally. We anticipate that these business moves will advance the ability of contract manufacturing of sterile products to meet the technological and capacity needs of the industry, with new facilities and technology as an answer to the issue of and problems associated with aging sterile product manufacturing facilities. This should also allow for contract manufacturers to better focus on efficiency and compliance. The challenge for the contract manufacturers will be to manage this growth while maintaining cost effectiveness, quality and compliance in a complex global environment.

    Conclusion
    Although we have seen increases in the issuance of Warning Letters by regulators, not all is bad in the world of sterile contract manufacturing. There are many firms that are investing in new facilities with newer designs, newer technologies and hopefully with an emphasis on:
    • Risk management implementation;
    • Knowledge management;
    • Personnel training;
    • Aseptic process understanding;
    • Smarter and more quality risk-oriented APS programs; and
    • State-of-the-art cleaning validations.
    More importantly, contract manufacturers should once and for all understand and embed in their DNA that they are not just a fiscally beneficial avenue to produce biopharmaceutical medicine, but an important, if not the most important, player in providing affordable health care for patients. Patient-centricity should be at the core of their philosophy. This will be good news for an industry that is in need of manufacturing outsourcing as a way to establish operational excellence and ensure reliable productivity. 

    References
    1. Deloitte 2016 Global life sciences outlook, Moving forward with cautious optimism, https://www2.deloitte.com/.../Life-Sciences.../gx-lshc-2016-life-sciences-outlook.pdf
    2. Indian Sterile Manufacturer receives a second Warning Letter, ECA 14-Jun-2017, http://www.gmp-compliance.org/gmp-news/indian-sterile-manufacturer-receives-a-second-warning-letter
    3. Paula Katz, Director, Manufacturing Quality Guidance and Policy Staff, Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research, FDA Compliance Trends, India Pharmaceutical FORUM 2017 – Towards Excellence in Quality Indian Pharmaceutical Alliance, Mumbai, India, Feb. 24, 2017

    Igor Gorsky is currently senior consultant at ConcordiaValsource, LLC. He has held multiple positions with increasing responsibility at Alpharma, Wyeth and Shire. He worked in production, quality assurance, technical services and validation, and was previously associate director of global pharmaceutical technology at Shire Pharmaceuticals.
    Related Searches
    • Pharmaceutical manufacturing
    • study
    • Outsourcing
    • patients
    Suggested For You
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Pfizer, BioNTech To Supply 200M More Vax Doses to EU Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    Trial Runners Trial Runners
    A Potential “Marriage” A Potential “Marriage”
    Inspecting the Unexpected Inspecting the Unexpected
    SGS Life Sciences SGS Life Sciences
    Taros Chemicals Taros Chemicals
    Sekisui Sekisui
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Primary Packaging Considerations Amid COVID-19 Vax Urgency Primary Packaging Considerations Amid COVID-19 Vax Urgency
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Tropichem Becomes Vetio Tropichem Becomes Vetio

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login